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INTRODUCTION
 Coronary stenting is an established form of 
the treatment for the majority of patients with 
symptomatic coronary artery disease (CAD). Stents 
innovation made a revolution in the treatment 
of CAD but in stent restenosis remain as a major 
limitation of coronary artery stenting in daily 
clinical practice not least in high-risk patients such 
as those with diabetes or longer lesions.1-3
 Randomized controlled trials have shown 
that drug-eluting stents (DES) have resulted in a 
substantial decrease in restenosis across a wide 
range of coronary lesions and patient subsets 
compared to bare metal stents (BMS).3,4 Also DESs 
could effectively improve 1-year clinical outcome 
in ‘real world’ practice.5,6 However, recently, late 
thrombosis, as a complication of DES, arouse many 
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ABSTRACT
Objective: To compare one year clinical outcomes of patients with chronic stable angina who underwent 
implantation of bare metal stent (BMS) or drug eluting stent (DES).
Methodology: Four hundred forty two (442) participants of OPCES study (Osvix versus Plavix in Cardiovascular 
Events after Stenting) were included in this sub-study. After evaluation of exclusion criteria (combined 
DES and BMS stenting (n=31) and incomplete data (n=48) patients were divided in two groups according 
to selected stent(DES or BMS). Follow-up was conducted by a structured telephone interview after 6 
and 12 months. The patients’ documents were reviewed by the Study Event Committee in the Isfahan 
Cardiovascular Research Center to evaluate the occurrence of study endpoints which consisted of clinical 
success	rate	and	major	adverse	cardiac	events	(Major	Adverse	Cardiac	Events	(MACE),	cardiac	death,	non-
fatal	MI,	target	vessel	revascularization	and	stroke)	in	hospital,	after	6	and	12	months.
Results: One hundred sixty six (45.7%) patients were in the DES and 197(54.3%) were in the BMS group. 
Procedural	 complications	 were	 seen	 more	 frequently	 in	 the	 DES	 group	 (1.0%	 vs.	 4.8%,	 P=0.027),	 the	
prevalence	of	the	in-hospital	MACE,	angiographic	and	clinical	success	rate	were	the	same	between	both	
the	groups.	There	was	no	significant	difference	regarding	6	and	12	months	MACE	rate	in	patients	treated	
by	BMS	or	DES	(6	months:	1.1%	vs.	0.6%,	p>0.999	12	month:	3.4%	vs	2.6%,	P	=	0.755).
Conclusion:	Considering	the	same	clinical	outcome	and	the	economical	parameters,	use	of	the	BMS	after	
proper patient selection are recommended. 
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cardiac events.
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DES vs. BMS
questions about the safety and efficacy of these 
stents.7-10 Recent studies suggest a 0.5% increased 
long-term thrombosis risk with DES; however, the 
clinical significance of these events remains under 
debate11 and in a real-world setting, use of DES in 
all patients is less cost effective than in studies with 
selected patients.12
 In Iran, long-term clinical outcome of stenting by 
DES versus BMS were compared in a few studies 
but all of them were based on single center registries 
or trials. In present study we aimed at comparing 
the 1-year clinical outcomes of the patients who 
underwent BMS or DES placement in the Iranian 
patients’ subsets participating in the multicentric 
study.
METHODOLOGY
 The present study was a case-cohort ancillary 
study included in the Osvix versus Plavix in 
Cardiovascular Events after Stenting (OPCES) 
study.13 Briefly, OPCES is a randomized, double 
blind, multi-centric clinical trial which compared 
the early and late cardiovascular events as well 
as side effects of Osvix versus Plavix, two generic 
form of Clopidogrel, regimens in patients with 
chronic stable angina who underwent Drug eluting 
or bare metal stenting. The study was approved by 
the ethical committee of the Isfahan Cardiovascular 
Research Center, a WHO collaborating center, and 
all patients provided written informed consents 
for participation. OPCES study was registered in 
Iranian Randomized Clinical Trial with register 
No: IRCT138712111723N1. Study protocol and 
procedural details were mentioned before.13 In 
brief, stent placement procedures were performed 
according to standard methods and the selection of 
stent Type, the size of any devices and the pressure 
used during dilation were dependent on the 
operator’s discretion.
 Furthermore, Choice of stent was partly 
influenced by the participant’s financial situation. 
DES is more expensive than BMS in the market. 
Lesion types were noted according to the American 
College of Cardiology/American Heart Association 
(ACC/AHA) lesion characteristics classification14 
and Thrombolysis in Myocardial Infarction (TIMI) 
flow grade, were determined by visual estimation 
using the guiding catheter as a reference object for 
calibration.
 After successful percutaneous coronary 
intervention (PCI) each participant was considered 
as eligible for follow-up which was conducted by 
a structured telephone interview with the patients 
or one of his(er) immediate relatives up to one 
year. In the presence of any events the patient was 
evaluated by his(er) cardiologist at first and all 
patient’s documents were reviewed by the Study 
Event Committee in the Isfahan cardiovascular 
research center for evaluation of his(er) event`s 
documents to decide about the occurrence of study 
endpoints.
Patients: From March 2007 to November 2009, 442 
patients were included in the OPCES study. In our 
study exclusion criteria were combined DES and 
BMS stenting (n=31), and incomplete data (n=48). 
Two hundred seventy four (75.5%) and 23(6.3%) 
of the patients were enrolled in Isfahan centers 
(University and Private Hospitals, respectively). 
Other patients were enrolled in Shiraz (28(7.7%)), 
Tabriz (14(3.9%)), Mashhad 6(1.7%)) and Khoram 
Abad (18(5.0%) centers.
Definition: Myocardial infarction (MI) was defined 
by Ischemic symptoms accompany by at least one 
of the following criteria: positive cardiac enzymes, 
electrocardiographic changes (pathologic Q wave 
or new ST changes) and new cardiac motion 
abnormality on echocardiographic or radionuclide 
imaging. Non-Qwave MI was defined as a 5-fold 
increase in MB fraction of creatinine kinase without 
the development of new Q waves. Angiographic 
success was defined as residual stenosis <20% plus 
normal TIMI flow grade three in the target vessel. 
Clinical success was defined as angiographic success 
in all target lesions without any in-hospital major 
adverse cardiac events (In-hospital MACE: death, 
MI, emergency bypass surgery or PCI) during 
hospitalization. Early and late MACE were defined 
as the presence of cardiac death, non-fatal MI, or 
target vessel revascularization (TVR) or stroke 
during the 6 and 12 months of follow-up period, 
respectively. TVR was defined as ischemia-driven 
repeat percutaneous intervention or bypass surgery 
of the target vessel. Target lesion revascularization 
was defined as ischemia-driven repeat percutaneous 
intervention of the target lesion or bypass surgery 
of the target vessel.
Endpoints: The primary endpoint of this study was 
in-hospital MACE and clinical success rate. The 
secondary endpoints were consisted of early and 
late MACE.
Statistical analysis: Continuous variables are 
expressed as mean ± SD, and dichotomous 
variables as frequencies. Categorical variables were 
compared using the chi-square test (or Fisher’s 
exact test if required) and continuous variables by 
using student t test or Mann-Whitney U test and 
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p values < 0.05 were considered as statistically 
significant. Univariate and multivariate analyses of 
hazard ratios, including 95% confidence intervals, 
were calculated using the Cox proportional hazard 
method. Factors with p values <0.15 in the univariate 
analysis were entered into the multivariate model. 
All the statistical analyses were performed using 
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) for 
windows.
RESULTS
 Totally, 426 lesions in 363 patients (Lesion/
patient ratio: 1.16±0.39) were treated in this study. 
One hundred twenty three (33.9%) of the patients 
were female and their mean age was 59.07 ± 9.41 
years old. They were divided in two groups. 
197(54.3%) and 166(45.7%) patients were in BMS 
and DES group, respectively.
 Table-I reveals the clinical and demographic 
characteristics of the patients at baseline. As it 
shows patients in the DES group are more often 
diabetics (27.4% vs. 38.9%, P=0.013) and less 
frequently have positive smoking history (48.2% vs. 
32.5%, P=0.002). Other baseline characteristics are 
comparable between the groups.
 Table-II shows 216 lesion (Lesion/patient ratio: 
1.12±0.35) and 176 lesion (Lesion/patient ratio: 
1.06±0.27) were treated in the BMS and DES group, 
respectively. In the DES group, the lesions are more 
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Table-I: Baseline demographic, clinical and para 
clinical characteristics of the patients.
 BMS DES p value
Demographic characteristics
No of cases (%) 197(54.3) 166(45.7) 
Age  58.92±9.51 59.25±9.30 0.253
Female Gender 60(30.5) 63(38.0) 0.133
Height(cm) 165.04±10.33 164.72±9.91 0.775
Weight(kg) 71.91±12.95 73.42±11.75 0.253
Body Mass index 26.43±4.41 27.07±3.81 0.145
  (kg/m2)
Obese( BMI>30) 41(21.0) 34(20.5) 0.899
Osvix (vs. plavix)  97(49.2) 89(53.6) 0.406
  Consumption
Paraclinical characteristics  
FBS(mg/dl) 106.79±35.41 124.44±59.10 0.001
cr(mg/dl) 1.02±0.28 1.06±0.27 0.271
BUN(mg/dl) 15.80±4.81 15.64±4.72 0.764
Renal insufficiency 9(4.7) 15(9.2) 0.089
  (cr>1.5 mg/dl)
Clinical characteristics  
Multivessel disease  75(38.1) 59(35.5) 0.619
Low EF (<40%) 23(11.9) 18(11.0) 0.794
Wall motion abnormality* 84(43.1) 71(43.3) 0.967
Dyslipidemia† 126(64.3) 110(66.3) 0.694
Hypertension‡ 122(62.6) 112(67.9) 0.292
Diabetes mellitus 54(27.4) 66(39.8) 0.013
History of smoking§ 95(48.2) 54(32.5) 0.002
History of MI  102(51.8) 93(56.0) 0.419
History of CHF 3(1.5) 1(0.6) 0.403
History of Stroke  3(1.5) 3(1.8) 0.832
History of Peripheral  0(0.0) 2(1.2) 0.208
  vascular disease
Prior CABG  1(0.5) 0(0.0) >0.999
Prior PCI 11(5.6) 14(8.4) 0.285
Categorical variables are expressed as N (%) & Continuous 
variables are expressed as Mean ± SD
BMS, bare metal stents; DES, drug-eluting stents; Low EF=Left 
ventricular ejection fraction <40%; MI, Myocardial infarction; 
CHF, Congestive heart failure; CABG, Coronary artery bypass 
grafting; PCI, Percutaneous coronary intervention *diagnosed 
by Echocardiography †Dysipidemia: LDL cholesterol **1.0 
mg/dl, triglycerides **150 mg/dl and HDL ≤ 40 mg/dl or 
on treatment of Dyslipidemia ‡Hypertension: Systolic blood 
pressure > 140 mmHg or diastolic blood pressure > 90 mmHg or 
taking hypertensive drug § smoking: person smoking at least 1 
cigarette (or cigar, pipe) in the last month.
Table-II: Angiographic, lesion and procedural 
characteristics o the patients*
 BMS DES p value
Angiographic characteristics 
No of arteries (%) 216(50.7) 176(41.3) 
Lesions/patient Ratio 1.12±0.35 1.06±0.27 0.065
%Diameter stenosis 86.62±7.90 88.53±9.18 0.027
Preprocedural TIMI Flow  2.87±0.39 2.67±0.64 0.001
Target territory   <0.001
LAD 111(51.4) 138(78.4) 
LCX 38(17.6) 15(8.5) 
RCA 67(31.0) 23(13.1) 
Lesion characteristics   
ACC/AHA typing   <0.001
A 128(59.5) 35(20.1) 
B 73(34.0) 79(45.4) 
C 14(6.5) 60(34.5) 
Tubular(10< ≤20mm) 169(80.1) 55(32.5) <0.001
Diffuse(>20mm)  19(9.0) 114(67.5) <0.001
Total occlusion 13(6.0) 30(17.0) 0.001
Direct stenting  138(66.7) 65(38.2) <0.001
Stent length  14.64±4.40 25.46±8.21 <0.001
Stent diameter  3.12±0.41 2.94±0.26 <0.001
Postprocedural stenosis % 2.14±10.34 4.17±18.09 0.192
Postprocedural TIMI Flow  3.00±0.00 2.97±0.2 0.059
Angiographic success rate 214(99.1) 170(96.6) 0.084
Categorical variables are expressed as N(%) & Continuous 
variables are expressed as mean ± SD
BMS, bare metal stents; DES, drug-eluting stents; LAD, left 
anterior descending; LCX, left circumflex artery;
RCA, right coronary artery; ACC/AHA, American college of 
cardiology/American heart association
*Lesion-based Analysis
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complex, diffuse, stenotic and located in the tighter 
vessels than the BMS group. They are located 
more frequently in the LAD territory and also total 
occlusion was observed more frequently in them. 
 Although, procedural complications were seen 
more frequently in the DES group (1.0% vs. 4.8%, 
P=0.027) but the prevalence of the in-hospital 
MACE were the same in both groups (2.5% vs. 
2.4%, P=0.938)(Table-III). Also Angiographic and 
clinical success rate were the same in BMS vs. DES 
groups (99.1% vs. 96.6%, p=0.084; 96.4% vs. 94.0%, 
_P=0.267, respectively).
 After exclusion of the patients with failed PCI 
(n=17), 346(95.3%) patients were eligible for follow 
up. The response rate during one year of follow-
up was 95.4% which was significantly different 
between the groups (92.1% in BMS vs. 99.4% in DES 
group, p=0.001).There was no significant difference 
regarding early and late MACE in patients treated 
by BMS vs. DES (1.1% vs. 0.6%, p>0.999; 3.4% vs. 
2.6%, p=0.755, respectively) (Table-IV). The study 
groups had the same frequency of MI, cardiac 
death, stroke and TVR (Table-IV). Multivariate 
analysis reveals that no factor had a predictive role 
in developing the MACE.
DISCUSSION
 DES implantation has been proved to markedly 
reduce the incidence of early restenosis and repeat 
revascularization in clinical trials or daily practice 
population.3-6 But during the past decade questions 
about DES safety and long term results are being 
asked.3
 The BASKET-LATE15 (Basel Stent Kosten-
Effekivitats Trial- Late Thrombotic Events) 
Investigators present the long-term follow-up of a 
cohort of patients from the BASKET trial, a study 
of a randomized comparison of BMS with DES 
among a broad spectrum of unselected patients 
from a single practice. In the BASKET trial, all 
patients received the combination of aspirin 
plus clopidogrel for 6 months; after the cessation 
of clopidogrel, the investigators prospectively 
followed patients who had had survived the first 
6 months without an ischemic event. Between 7 
and 18 months, they observed an increase in the 
death/ myocardial infarction composite among 
the DES patients compared with the BMS patients 
(adjusted hazard ratio 2.2, P=0.03). Their conclusion 
DES vs. BMS
Table-III: Procedural characteristics, complications 
and Primary Endpoints 
 BMS DES p value
Procedural characteristics 197(54.3) 166(45.7) 
MVPCI (%) 36(18.3) 23(13.9) 0.256
Most complex Lesion   <0.001
  (ACC/AHA typing)
A 113(57.7) 34(20.6) 
B 68(34.7) 74(44.8) 
C 15(7.7) 57(34.5) 
Procedural complications 2(1.0) 8(4.8) 0.027
Dissection 1(0.5) 4(2.4) 0.121
Percutaneous arterial 1(0.5) 3(1.9) 0.334
  complication
Slow Flow/No reflow 0(0.0) 2(1.2) 0.208
Coronary artery perforation 0(0.0) 1(0.6) 0.457
Side Branch Occlusion 0(0.0) 1(0.6) 0.457
Acute segment closure 0(0.0) 1(0.6) 0.457
LOS 3.12±1.79 3.40±2.23 0.185
Inhospital MACE  5(2.5) 4(2.4) 0.938
Emergent CABG 0(0.0) 1(0.6) 0.457
Q wave MI 1(0.5) 3(1.8) 0.336
NonQ wave MI 3(1.5) 1(0.6) 0.354
Death 1(0.5) 1(0.6) >0.999
CSR 190(96.4) 156(94.0) 0.267
Categorical variables are expressed as N(%) & Continuous 
variables are expressed as mean ± SD
BMS, bare metal stents; DES, drug-eluting stents; MVPCI, 
Multivessel percutaneous coronary intervention;
ACC/AHA, American college of cardiology/American heart 
association; LOS, Length of stay;
MACE, Major adverse cardiac events; CSR, Clinical success rate
*Patient-based Analysi
Table-IV: Follow up Data and secondary endpoints.
 BMS DES p value
Eligible to Follow 190 156 
Follow up Rate 175(92.1) 155(99.4) 0.001
Any Event 36(20.6) 23(14.8) 0.175
Readmit 33(18.9) 23(14.8) 0.332
Angina 21(12.0) 11(7.1) 0.133
Repeated PCI 6(3.4) 2(1.3) 0.290
CABG 1(0.61) 0(0.0) >0.999
TLR 1(0.6) 0(0.0) >0.999
Instent Restenosis 2(1.1) 1(0.6) >0.999
Early MACE (6 months) 2(1.1) 1(0.6) >0.999
Late MACE (12 months) 6(3.4) 4(2.6) 0.755
TVR 3(1.7) 0(0.0) 0.250
Cardiac Death 2(1.1) 1(0.6) >0.999
Stroke 0(0.0) 1(0.6) 0.470
MI 1(0.6) 1(0.6) >0.999
Categorical variables are expressed as N(%) & Continuous 
variables are expressed as mean ± SD
BMS, bare metal stents; DES, drug-eluting stents; PCI, 
Percutaneous coronary intervention;
CABG, Coronary artery bypass grafting; TLR, Target lesion 
revascularization;
MACE, Major adverse cardiac events; TVR, Target vessel 
revascularization; MI, Myocardial infarction.
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is carefully worded to note that there was an 
observed continued lesser incidence of target vessel 
revascularization with the DES and that the late 
clinical events.
 But our study could not reveal any significant 
difference regarding primary endpoints or early 
and long term MACE between DES and BMS 
groups. In fact the rate of MACE in our study was 
more lower than the BASKET and the basket late 
(7.2% DES and 12.1% BMS in 6 months and 9.3% 
DES and 7.9% BMS between 6 and 18 months of 
follow up).12 Also in our study MACE pattern was 
not the same as BASKET (time dependant) at least 
in 12 months.
 In this regard our results are comparable with 
the Alidoosti`s study.16 They evaluated long-term 
clinical outcome of the DES vs. BMS based on their 
single center registry (1796 patients: 228 DES and 
1568 BMS) and they did not find any statistically 
significant difference between those groups in 
terms of angiographic and clinical success rates 
(P=0.72 and P=0.097, respectively). Although, 
the rate of MACE during follow-up was not 
significantly different between DES(2.2%) and BMS 
(4.2%), they reported that the risk of MACE was 
about one third when DES was compared with BMS 
(hazard ratio=0.36, 95% CI 0.13-0.95) which was not 
confirmed in our study. 
 We think that lower rate of MACE in Iranian 
population comparing to other countries is an 
important finding which must be investigated 
in more powerful studies. At first, we have the 
hypothesis that the same clinical outcome of DES 
and BMS groups in our study, in regard of some 
other studies3-6, could be explained by the point that 
patients of the DES group have higher risk profile 
than the BMS group. They are more diabetic and 
they have more diffuse and complex lesions in 
the smaller vessels. Therefore, longer stents with 
smaller dimensions were implanted (P<0.001). 
After more analysis we conclude that although 
this hypothesis could explain the cause of more 
procedural complications rate in the DES group but 
it could not explain the cause of the same results in 
secondary endpoints, the mentioned factors did not 
play any role in the development of MACE in the 
multivariate analysis after adjusting for differences 
in baseline characteristics. 
 AS mentioned before, the patients in the DES 
group were more compliant by the Follow-up 
protocol. It could be related to different socio-
economical status of the patients. Furthermore, 
high cost of the DES and higher risk profile of these 
patients may encourage them to be more compliant 
with the study follow-up protocols.
Study limitation: The choice between the two stent 
types was partly subject to the patients’ financial 
situation, leading to possible selection bias. For the 
evaluation of effects of drug-eluting stents use dur-
ing long-term follow up, further studies on larger 
populations are required.
CONCLUSION
 In view of the same clinical outcome and the 
economical parameters, use of the BMS after proper 
patient selection are recommended. Of course 
further studies on large number of patients  are 
needed to confirm our findings.
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